• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository

by Fred Pennic 10/20/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
JPC Taps Proscia to Modernize World's Largest Human Tissue Repository

What You Should Know:

– The U.S. government’s Joint Pathology Center, which houses the world’s largest human tissue repository, today announced that Proscia, a leading digital and AI pathology company, will provide end-to-end modernization of JPC’s pathology operations.

– The multi-phase project will digitize the world’s largest human pathology specimen repository in order to enhance biomedical research for cancer and infectious diseases like COVID-19, and enable easier data sharing with researchers, diagnosticians, and educators to facilitate medical advances.

– The digitization of JPC’s repository will also unlock previously untapped medical data in order to accelerate the development of AI-powered pathology applications for building personalized therapeutics.


Joint Pathology Center (JPC), the premiere pathology reference center for the U.S. government, has selected Proscia’s Concentriq platform for a complete transformation of its pathology practice.  Proscia is a Philadelphia, PA-based provider of digital and computational pathology solutions.

Modernize World’s Largest Human Tissue Repository

The Joint Pathology Center seeks to preserve, modernize, and grow the nation’s oldest tissue repository to promote biomedical research. Over the past century, it has collected approximately 55 million glass slides, 31 million paraffin-embedded tissue blocks, and over 500,000 wet tissue samples, which have provided critical insight into our understanding of current and future disease; data from the repository was used to sequence the 1918 influenza virus that killed more than 40 million people worldwide and can similarly help us to combat COVID-19. The rise of digital pathology, which captures high-resolution images of tissue specimen, is enabling JPC to realize even more value from its data by making it readily accessible to clinicians, pathologists, and healthcare data analysts. Digital pathology also gives way to the introduction of computational pathology applications leveraging artificial intelligence to unlock new insights that drive drug discovery and routine diagnosis.

At the center of this modernization effort, JPC will digitize its tissue archive, the world’s largest repository of human pathology specimen, to capitalize on this invaluable source of medical data. The digital repository will provide increased access to data for driving medical advances related to infectious diseases and cancer as well as accelerate the development of computational pathology applications establishing diagnosis, prognosis, and personalized therapies for patients.

Proscia’s Concentriq Platform to Serve As Foundation for Digital and Computational Pathology

As digitizing the world’s largest human tissue archive depends on scalable software infrastructure, JPC has selected Proscia’s Concentriq digital and computational pathology platform to provide this foundation. Concentriq is a singular image and data management platform that unifies pathology operations across the connected enterprise and accelerates workflows. With Concentriq, JPC will provide its network of researchers with intuitive, secure access to its data and streamline collaboration, enabling them to more easily analyze thousands of diseases and find new ways to fight them. Additionally, JPC will deploy Concentriq to digitize its routine pathology consultations and overcome the delays that result from sharing physical specimen in an effort to improve patient outcomes by providing accurate, timely pathology findings.

Why It Matters

Digitizing the repository also holds significant potential for advancing the development of computational pathology applications spanning diagnosis, prognosis, and personalized care. Training and validating even a single application requires massive volumes of images to ensure that it can account for the variability seen in practice, and JPC’s archive is unmatched in its ability to provide this data for countless diseases and use cases. As JPC delivers these applications, it can deploy them, along with other computational solutions, into its research and clinical workflows leveraging Proscia’s Concentriq.

“JPC’s modernization effort marks a monumental leap forward for the field of pathology, and we’re excited to be a part of it,” said David West, CEO of Proscia. “Concentriq sits at the intersection of digital and computational pathology across research and clinical practice, providing JPC with the tools needed to finally realize the full promise of its data and transform routine diagnosis.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, Artificial Intelligence, cancer, clinical data repository, clinical workflows, data management, Digital Pathology, Drug Discovery, Healthcare Data, Proscia

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |